Schizophrenia | Disease Landscape & Forecast | G7 | 2022

The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for the late-phase and recently approved therapies not specifically targeting schizophrenia subpopulations with high unmet need—including new oral atypical antipsychotics (e.g., Alkermes’s Lybalvi), new LAIs (e.g., Janssen’s paliperidone six-month depot, Teva’s TV-46000), and other agents with novel mechanisms of action (e.g., Sunovion / Sumitomo Dainippon Pharma / Otsuka’s ulotaront [SEP-363856], Karuna Therapeutics’ KarXT). Although the potential of therapies in development to treat the negative symptoms of schizophrenia or the cognitive impairment associated with schizophrenia (CIAS) remains to be seen in late-phase studies, some agents had promising results in mid-phase clinical studies and could earn blockbuster sales, such as Acadia Pharmaceuticals’ pimavanserin and Boehringer Ingelheim’s BI 425809.

Questions Answered

  • What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
  • What percentage of diagnosed lifetime prevalent schizophrenia patients receive drug treatment? How large are the schizophrenia subpopulations with negative symptoms or cognitive impairment?
  • What are the greatest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs?
  • How will novel emerging therapies be positioned in the schizophrenia treatment algorithm?

Geographies: United States, EU5, Japan.

Primary research: 26 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; drug-treated prevalence of schizophrenia by country.

Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2031, segmented by brands / generics.

Emerging therapies: Phase III / PR: 11 drugs. Coverage of select Phase II and Phase I products.

Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement: Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report